Eiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The company has a fifty day moving average price of $4.52 and a 200-day moving average price of $6.86. Eiger BioPharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $43.35. The company has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.